Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Oxytocin

Pitocin, Syntocinon

Quick Stats
Studies 93
Trials 100
Score 4
2025 pubmed

Heartfulness meditation alters neuroendocrine profiles: A randomized controlled trial on hormones of stress and well-being.

Philip. Sanjana T ST; Thimmapuram. Jayaram J; Thakur. Kapil K; Dayal. Navami N; Patil. Yogesh Y; Sabbu. Kishore K; Surve. Samruddhi S; Patil. Poonam P; Thakur. Mansee M

Key Findings

  • Meditation depth and positive affect increased, negative affect decreased
  • Serum oxytocin rose by ~88 pg/mL and β‑endorphins by ~95 pg/mL
  • Cortisol dropped by ~134 pg/mL, with cortisol inversely linked to oxytocin and endorphins

Practical Outcomes

  • Practicing guided Heartfulness meditation daily for about a month can naturally raise oxytocin and endorphin levels and lower cortisol, leading to better mood and stress tolerance. This protocol is low‑cost, non‑pharmacological, and can be added to existing biohacking routines for mental health benefits.

Summary

A 30‑day Heartfulness meditation program boosted the “feel‑good” hormones oxytocin and β‑endorphins and cut the stress hormone cortisol, while also improving mood and meditation depth, showing a simple, drug‑free way to enhance stress resilience and well‑being.

Abstract

Chronic stress disrupts the neuroendocrine system, leading to imbalances in neurotransmitters and stress hormones such as oxytocin, β endorphins and cortisol, contributing to mood disorders and poor emotional regulation. Complementary and alternative practices like meditation have shown promising results in stress regulation and mood elevation. Heartfulness (HFN) meditation, rooted in yogic traditions and incorporating yogic transmission, is an emerging technique to improve emotional resilience and hormonal homeostasis. Therefore, this study aimed to evaluate the effects of HFN meditation on oxytocin, β-endorphins, and cortisol. It also evaluated the changes in meditation depth using validated psychometric tools. A randomized controlled trial was conducted. Participants were divided into experimental and control groups. The experimental group practiced guided HFN meditation for 30 days. Following this, a crossover design was implemented in which, the control group participants were now given the intervention of HFN meditation. Biochemical markers (serum oxytocin, β-endorphins, cortisol) were measured at day 30, and day 60. Psychometric assessments included the Meditation Depth Questionnaire and the Positive and Negative Affect Schedule (PANAS). HFN meditation significantly improved meditation depth (ΔM = -14.87, 95% CI [-23.61,-6.13], P = .001, r = 0.333) and positive affect (ΔM = -8.48, 95% CI [-12.03,-4.93], P < .001, r = 0.29), while reducing negative affect (ΔM = 7.70, 95% CI [3.81, 11.60], P < .001, r = 0.21). Oxytocin and endorphin levels increased (oxytocin ΔM = +88.18, P = .003, r = 0.355 and endorphin ΔM = +94.83, P = .003, r = 0.357), and cortisol decreased (ΔM = -133.55, P < .001, r = 0.661). After crossover, the control group exhibited similar improvements. Negative correlations were found between cortisol and both oxytocin and β-endorphins. HFN meditation significantly modulates stress-related neuroendocrine markers and enhances positive emotional states. By increasing the levels of these happy hormones and reducing cortisol, HFN presents a promising non-pharmacological intervention for improving mental health and stress resilience.

Study Information

Provider

pubmed

Year

2025

Date

2025-11-21T00:00:00.000Z

DOI

10.1097/md.0000000000045559